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SAMHD1 is a cellular enzyme that depletes intracel-
lular deoxynucleoside triphosphates (dNTPs) and
inhibits the ability of retroviruses, notably HIV-1, to
infect myeloid cells. Although SAMHD1 is expressed
in both cycling and noncycling cells, the antiviral
activity of SAMHD1 is limited to noncycling cells.
We determined that SAMHD1 is phosphorylated on
residue T592 in cycling cells but that this phosphory-
lation is lost when cells are in a noncycling state.
Reverse genetic experiments revealed that SAMHD1
phosphorylated on residue T592 is unable to block
retroviral infection, but this modification does not
affect the ability of SAMHD1 to decrease cellular
dNTP levels. SAMHD1 contains a target motif for
cyclin-dependent kinase 1 (cdk1) (592TPQK595), and
cdk1 activity is required for SAMHD1 phosphoryla-
tion. Collectively, these findings indicate that phos-
phorylation modulates the ability of SAMHD1 to
block retroviral infection without affecting its ability
to decrease cellular dNTP levels.
INTRODUCTION
Efficient infection of human primary macrophages, dendritic
cells, and resting CD4+ T cells by macaque simian immunodefi-
ciency virus (SIVmac) requires the accessory protein Vpx (Arfi
et al., 2008; Baldauf et al., 2012; Descours et al., 2012; Goujon
et al., 2003, 2007, 2008). Vpx is essential for both SIV infection
of primary macrophages and viral pathogenesis in vivo (Belshan
et al., 2006; Fletcher et al., 1996; Gibbs et al., 1995; Hirsch et al.,
1998). Vpx is incorporated into viral particles, suggesting that it
might act immediately after viral fusion (Jin et al., 2001; Kappes
et al., 1993; Park and Sodroski, 1995; Selig et al., 1999). Viral
reverse transcription is prevented in primary macrophages
when cells are infected with either Vpx-deficient SIVmac or
HIV-2 (Bergamaschi et al., 2009; Fujita et al., 2008; Goujon
et al., 2007; Kaushik et al., 2009; Srivastava et al., 2008). Interest-
ingly, Vpx also increases the ability of HIV-1 to efficiently infectCell Hmacrophages, dendritic cells, and resting CD4+ T cells when
Vpx is incorporated into HIV-1 particles or supplied in trans
(Baldauf et al., 2012; Descours et al., 2012; Goujon et al.,
2008; Sunseri et al., 2011). Recent work identified SAMHD1 as
the protein that blocks infection of SIVDVpx, HIV-2DVpx, and
HIV-1 before reverse transcription in macrophages, dendritic
cells, and resting CD4+ T cells (Baldauf et al., 2012; Berger
et al., 2011; Descours et al., 2012; Hrecka et al., 2011; Laguette
et al., 2011). Mechanistic studies have suggested that Vpx in-
duces the proteasomal degradation of SAMHD1 (Berger et al.,
2011; Hrecka et al., 2011; Laguette et al., 2011). In agreement
with this, the C-terminal region of SAMHD1 contains a Vpx bind-
ing motif, which is important for the ability of Vpx to degrade
SAMHD1 (Ahn et al., 2012; Laguette et al., 2012; Lim et al.,
2012; Zhang et al., 2012). SAMHD1 is a deoxyguanosine triphos-
phate (dGTP)-regulated deoxynucleotide triphosphohydrolase
(dNTPase) that decreases the overall cellular levels of dNTPs
(Goldstone et al., 2011; Kim et al., 2012; Lahouassa et al.,
2012; Powell et al., 2011). Taken together, these results sug-
gested that an overall decrease on the level of dNTPs is respon-
sible for the block imposed on lentiviral reverse transcription.
SAMHD1 comprises the sterile alpha motif (SAM) and histi-
dine-aspartic (HD) domains. The HD domain of SAMHD1 is a
dGTP-regulated dNTPase that decreases the cellular levels of
dNTPs (Goldstone et al., 2011; Kim et al., 2012; Lahouassa
et al., 2012; Powell et al., 2011). In agreement with this, the
sole HD domain is sufficient to potently restrict infection by
different viruses (White et al., 2013). The HD domain is also
necessary for the ability of SAMHD1 to oligomerize and to bind
RNA (White et al., 2013). The decrease in dNTP levels in myeloid
cells correlates with the inability of lentiviruses to undergo
reverse transcription. Even though it is known that SAMHD1
blocks lentiviral infection by depleting the pool of dNTPs, the
regulation of the antiviral activity of SAMHD1 is not understood.
Remarkably, cycling and noncycling cells can express
SAMHD1; however, SAMHD1’s antiviral activity is only observed
in noncycling cells. Several examples illustrate the fact that
SAMHD1 is antivirally active in noncycling cells. Human mono-
cytic THP-1 cells that endogenously express SAMHD1 restrict
HIV-1 when cells are differentiated to a noncycling state by treat-
ment with phorbol-12-myristate-13-acetate (PMA) (Schwende
et al., 1996). Similarly, the human monocytic U937 cells stably
expressing an exogenous FLAG-tagged SAMHD1 protein onlyost & Microbe 13, 441–451, April 17, 2013 ª2013 Elsevier Inc. 441
Figure 1. Phosphorylation State of SAMHD1 in
Cycling and Noncycling Cells
(A) Endogenously expressed SAMHD1 was immunopre-
cipitated using anti-SAMHD1 antibodies from PMA-
treated (noncycling) or untreated (cycling) human
monocytic THP-1 cells. Proteinswere separated bySDS-
PAGE, and a Coomassie-blue-stained band containing
the SAMHD1 protein was subjected to phosphopeptide
mapping by mass spectrometry. The ratios of phos-
phorylated to unphosphorylated peptides are shown. The
ability of the different cells to restrict HIV-1 is presented.
Similar analysis was performed for determining the
phosphorylation state of the endogenously expressed
SAMHD1 in human MDMs. In parallel, PMA-treated or
untreated human monocytic U937 cells stably express-
ing SAMHD1-FLAG were used to immunoprecipitate
and determine the phosphorylation state of SAMHD1,
as described in Experimental Procedures. Mass-spec-
trometry analysis was performed three times, and a
representative experiment is shown. See also Figure S1.
(B) Wild-type (WT) human SAMHD1 protein is depicted
showing the numbers of the amino acid residues at
the boundaries of each domain. The residue T592 is
depicted in the consensus motif 592TPQK595 for recog-
nition and phosphorylation by cdk1.
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Phosphorylation Controls SAMHD1 Antiviral Activityrestrict HIV-1 when cells are differentiated with PMA to a noncy-
cling state. In addition, endogenous expression of SAMHD1 by
noncycling cells such asmacrophages and dendritic cells shows
potent restriction of HIV-1 infection. More recently, it was discov-
ered that noncycling resting CD4+ T cells potently block HIV-1
infection (Baldauf et al., 2012; Descours et al., 2012). By
contrast, the cycling human HeLa and 293T cells that endoge-
nously express SAMHD1 did not show activity against HIV-1
even when SAMHD1 was overexpressed.
This work explores the molecular basis by which SAMHD1
blocks HIV-1 infection only when expressed in noncycling cells.
Our mass-spectrometry findings revealed that SAMHD1 is un-
phosphorylated at position T592 in noncycling cells. By contrast,
SAMHD1 is phosphorylated at position T592 in all the cycling
cells studied here. We studied the role of T592 phosphorylation
in the ability of SAMHD1 to block retroviral infection by replacing
T592 with phosphomimetic or unphosphorytable residues.
SAMHD1 variants with a phosphomimetic residue at position
592 revealed that a phosphorylated SAMHD1 is unable to block
retroviral infection without affecting the ability of SAMHD1 to
decrease the cellular levels of dNTPs or the intrinsic enzymatic
dNTPase activity of the protein. We also showed that the ability
of phosphorylation to regulate restriction requires theHDdomain
and the C-terminal residues 583–626 of SAMHD1. Finally, we
explored the nature of the kinase that might be phosphorylating
SAMHD1 in cycling cells.
RESULTS
SAMHD1 Exhibits Differential Phosphorylation when
Comparing Cycling and Noncycling Cells
SAMHD1 is expressed in cycling and noncycling cells; however,
the ability of SAMHD1 to block infection by different retroviruses
is only observed in noncycling cells (Baldauf et al., 2012; Berger
et al., 2011; Descours et al., 2012; Hrecka et al., 2011; Laguette
et al., 2011;White et al., 2013). To find themolecular basis for this442 Cell Host & Microbe 13, 441–451, April 17, 2013 ª2013 Elsevierphenotype, we explored the state of SAMHD1 phosphorylation
in cycling and noncycling cells by using mass spectrometry.
Immunoprecipitated SAMHD1 proteins from cycling and non-
cycling cells were separated by SDS-PAGE and analyzed by
mass spectrometry (Figure S1 available online). Interestingly,
we observed that SAMHD1 is phosphorylated at residue T592
whenendogenously expressed in cycling THP-1 cells (Figure 1A).
Similarly, cycling human monocytic U937 cells, which do not
exhibit detectable levels of endogenous SAMHD1, engineered
to stably express SAMHD1-FLAG (U937-SAMHD1-FLAG) re-
vealed a phosphorylated SAMHD1-FLAG protein at residue
T592 (Figure 1A). By contrast, noncycling cells, such as THP-1
and U937-SAMHD1-FLAG cells differentiated to a noncycling
state by PMA, exhibited a SAMHD1 protein unphosphorylated
at position T592 (Figure 1A). These results correlated the phos-
phorylation state of SAMHD1with its antiviral activity (Figure 1A).
Because these experiments suggested that unphosphorylated
SAMHD1 is antivirally active, we tested the state of SAMHD1
phosphorylation in human primary monocyte-derived macro-
phages (MDMs). Similarly, we analyzed immunoprecipitated
SAMHD1 from human primaryMDM viamass spectrometry (Fig-
ure S1). In agreement with our findings, human primary MDMs
contained an unphosphorylated SAMHD1 in position T592 (Fig-
ure 1A). We also found that a small fraction of SAMHD1 was
phosphorylated in position S33; however, this phosphorylation
did not change when comparing cycling with noncycling cells
(Figure 1).
Our results suggest that unphosphorylated SAMHD1 on
T592 in noncycling cells is antivirally active and that phosphory-
lated SAMHD1 on T592 in cycling cells is antivirally inactive
(Figure 1B).
Phosphorylation Analysis of SAMHD1 in Different
Human Cell Lines and Primary Cells
To analyze the phosphorylation state of SAMHD1 in different hu-
man cell lines and primary cells, we studied the phosphorylationInc.
Figure 2. Phosphorylation State of SAMHD1 in Different Human Cell
Lines and Primary Cells
(A) 293T or HeLa cells transfected with a plasmid expressing SAMHD1-FLAG
or pLPCXwere lysed 24 hr after transfection and treated or not with lPP, which
is a protein phosphatase with activity toward phosphorylated serine, threo-
nine, and tyrosine residues. Protein samples were separated by SDS-PAGE
containing Phos-tag (+Phos-tag), a ligand that shifts the mobility of phos-
phorylated proteins, and analyzed by western blotting using FLAG antibodies.
We also analyzed the phosphorylation state of endogenously expressed
SAMHD1 proteins using anti-SAMHD1 antibodies in different cells: human
THP-1 cells, human primary MDMs, human primary resting CD4+ T cells, and
replicating CD4+ T cells. Protein samples were also separated in SDS-PAGE
gels without Phos-tag (Phos-tag).
(B) Similarly, we analyzed the phosphorylation state of SAMHD1-FLAG stably
expressed in U937 cells in the presence or absence of PMA. As a loading
control, cell lysates were western blotted using GAPDH antibodies.
(C) The phosphorylation state of SAMHD1 in resting and replicating CD4+
T cells from two donors was analyzed by using a specific antibody that
recognizes a phosphorylated SAMHD1 at position T592 (anti-phospho-
T592-SAMHD1). As a control, we analyzed the samples by western blotting
using anti-SAMHD1 and anti-GAPDH antibodies. Similar results were ob-
tained in three independent experiments, and a representative experiment
is shown.
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ing Phos-tag, a ligand that shifts the mobility of phosphorylated
proteins (Kinoshita et al., 2006). Initially, we analyzed transfected
SAMHD1-FLAG in human 293T cells. As shown in Figure 2A,
SAMHD1-FLAG transfected in 293T cells showed a broadmigra-
tion pattern, reflecting the different phosphorylated forms ofCell HSAMHD1-FLAG. By contrast, SAMHD1 treated with lprotein
phosphatase (lPP) showed a faster-migrating, more compacted
band revealing the unphosphorylated form of SAMHD1. This
experiment showed that SAMHD1 is phosphorylated in human
293T cells, which is in agreement with the fact that 293T cells
stably expressing SAMHD1-FLAG do not restrict retroviral
infection.
Next, we analyzed the phosphorylation of SAMHD1 in HeLa
cells (Figure 2A). Similarly, SAMHD1-FLAG transfected or stably
expressed in HeLa cells is phosphorylated, which is in agree-
ment with the fact that HeLa cells by themselves or stably ex-
pressing SAMHD1 do not restrict retroviral infection (data not
shown).
Because endogenously expressed SAMHD1 in THP-1 cells
only restricts when THP-1 cells are differentiated to a noncycling
state by using PMA, we compared the phosphorylation state of
SAMHD1 between cycling and noncycling THP-1 cells (Fig-
ure 2A). In agreement with our mass-spectrometry analysis, we
found that noncycling cells contained an endogenously ex-
pressed, unphosphorylated SAMHD1 protein. On the contrary,
SAMHD1 proteins from cycling THP-1 cells were phosphory-
lated. This evidence suggests that unphosphorylated SAMHD1
in noncycling THP-1 cells blocks retroviral infection.
Recent evidence demonstrated that SAMHD1 is responsible
for the block imposed by resting CD4+ T cells to HIV-1 infection
(Baldauf et al., 2012; Descours et al., 2012); therefore, we tested
the phosphorylation state of SAMHD1 in primary human resting
and replicating CD4+ T cells (Figure 2A). In agreement with the
hypothesis that unphosphorylated SAMHD1 is responsible for
retroviral restriction, we found that resting CD4+ T cells exhibit
an unphosphorylated SAMHD1 protein, whereas replicating
CD4+ T cells exhibit a phosphorylated SAMHD1 protein (Fig-
ure 2A). To further test the phosphorylation state of SAMHD1
in resting CD4+ T cells, we developed a rabbit polyclonal anti-
body for a peptide derived from SAMHD1 containing a phos-
phorylated T592 (anti-phospho-T592-SAMHD1). In agreement
with the Phos-tag results, we found that anti-phospho-T592-
SAMHD1 only recognized the SAMHD1 protein from replicating
CD4+ T cells (Figure 2C). These results are in agreement with our
hypothesis that the unphosphorylated form of SAMHD1 is
responsible for restriction.
We also analyzed the phosphorylation state of SAMHD1 in
human primary MDMs. As suggested by our mass-spectrometry
results, endogenously expressed SAMHD1 in human primary
MDMs is unphosphorylated (Figures 2A and 2B).
Finally, we analyzed the phosphorylation state of SAMHD1
in cycling and noncycling human monocytic U937 cells stably
expressing SAMHD1-FLAG (Figure 2B). Similarly, noncycling
U937 cells stably express SAMHD1-FLAG, which blocks retro-
viral replication and is unphosphorylated. Overall, our analysis
revealed that in all studied noncycling cells that restrict retroviral
infection, SAMHD1 is unphosphorylated, whereas cycling cells
contain a phosphorylated SAMHD1.
Regulation of SAMHD1 Restriction by Phosphorylation
Our biochemical analysis suggested that phosphorylated
SAMHD1 in cycling cells does not restrict retroviral infection.
To test the regulation of SAMHD1 restriction by phosphorylation,
we generated a series of SAMHD1 phosphorylation variantsost & Microbe 13, 441–451, April 17, 2013 ª2013 Elsevier Inc. 443
Table 1. SAMHD1 Phosphorylation Variants
SAMHD1 Variant HIV-1 Restrictiona Oligomerizationb RNA Bindingc Localizationd Cellular dATP Levele Enzymatic Activityf
WT + + + N low +
T592A + + + N low +
T592D  + + N low +
T592E  + + N low +
T592V + + + N low +
P593A + + + N low +
S33A + ND ND N ND ND
S33D + ND ND N ND ND
112-626 + + + C low +
112-626-T592D  + + C low +
S18A + ND ND N ND ND
S18D + ND ND N ND ND
T21A + ND ND N ND ND
T21D + ND ND N ND ND
T25A + ND ND N ND ND
T25D + ND ND N ND ND
WT, wild-type; ND, not determined.
aHIV-1 restriction wasmeasured by infecting U937 cells stably expressing the indicated SAMHD1 variants with HIV-1-GFP. After 48 hr, the percentage
of GFP-positive cells (infected cells) was determined by flow cytometry.
bOligomerization of the different SAMHD1 variants was determined by measuring the ability of the SAMHD1-FLAG variant to interact with the corre-
sponding SAMHD1-HA variant, as described in Experimental Procedures. ‘‘+ ’’ indicates 100% oligomerization, which corresponds to the amount of
wild-type SAMHD1-HA that interacts with wild-type SAMHD1-FLAG.
cSAMHD1-FLAG variants were assayed for their ability to bind the dsRNA analog ISD-PS, as described in Experimental Procedures. ‘‘+’’ indicates the
RNA binding achieved by wild-type SAMHD1.
dSubcellular localization of the different SAMHD1 variants in HeLa cells was performed as described in Experimental Procedures. ‘‘N’’ indicates
nuclear localization; ‘‘C’’ indicates cytoplasmic localization.
eThe cellular dATP levels of PMA-treated U937 cells stably expressing the different SAMHD1 variants were determined by primer extension as
described in Experimental Procedures. ‘‘Low’’ indicates similar to the dATP levels observed in PMA-treated U937 cells stably expressing wild-type
SAMHD1.
fThe enzymatic activity of the different SAMHD1 variants was measured by a dTTP hydrolysis reaction, as described in Experimental Procedures. ‘‘+’’
indicates wild-type levels of activity.
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phosphorytable (V and A) residue (Table 1). We initially analyzed
the phosphorylation state of the different variants via western
blotting using SDS-PAGE gels containing Phos-tag in human
293T cells (Figure 3A). Interestingly, SAMHD1 variants, wherein
T592 was replaced by a phosphomimetic or an unphosphoryt-
able residue, are not phosphorylated when compared to the
wild-type SAMHD1, suggesting that T592 is the residue phos-
phorylated in human cells (Figure 3A). To confirm that these
mutants were no longer phosphorylated in 293T cells, we tested
whether these proteins are recognized by the anti-phospho-
T592-SAMHD1 antibody. As shown in Figure 3B, the wild-type
SAMHD1 is recognized by the anti-phospho-T592-SAMHD1
antibody. By contrast, all variants wherein T592 was replaced
by a different residue were not recognized by anti-phospho-
T592-SAMHD1.
To test the ability of SAMHD1 variants to restrict HIV-1 infec-
tion in noncycling cells, we stably expressed SAMHD1 variants
in U937 cells (Figure 3C) and tested the ability of these cell lines
to restrict increasing amounts of HIV-1 expressing GFP as a
reporter for infection (HIV-1-GFP), as previously described
(Brandariz-Nun˜ez et al., 2012; White et al., 2013). As shown in
Figure 3D and Table 1, SAMHD1 containing a phosphomimetic444 Cell Host & Microbe 13, 441–451, April 17, 2013 ª2013 Elsevierresidue such as D or E lost the ability to block retroviral restriction
in noncycling U937 cells, suggesting that SAMHD1 phosphory-
lated at position T592 is unable to block retroviral infection. By
contrast, SAMHD1 variants wherein T592 was replaced by an
unphosphorytable residue such as V or A were not affected in
their ability to block infection by HIV-1-GFP (Figure 3D and
Table 1). Similar restriction patterns were observed when using
HIV-2, SIVDVpx, feline immunodeficiency virus, equine infec-
tious anemia virus, bovine immunodeficiency virus, and N-tropic
and B-tropic murine leukemia viruses (data not shown), as
described in White et al. (2013). These results suggest that a
phosphorylated SAMHD1 in position T592 is unable to restrict
infection by different retroviruses.
Our initial mass-spectrometry analysis of endogenously ex-
pressed SAMHD1 in THP-1 cells revealed that a small fraction
of SAMHD1was phosphorylated in position S33, and this pattern
did not change when comparing cycling with noncycling cells
(Figure 1A). To understand the contribution of S33 phosphoryla-
tion in the ability of SAMHD1 to restrict HIV-1 infection, we re-
placed S33 with a phosphomimetic (D) or an unphosphorytable
(A) residue. SAMHD1 variants were stably expressed in U937
cells (Figure S2A), and the ability of these variants to restrict
HIV-1-GFP was measured (Figure S2B). As shown in Figure 3E,Inc.
Figure 3. Ability of SAMHD1 Phosphorylation
Variants to Restrict HIV-1
(A) Human 293T cells were transfected with wild-type
or the indicated SAMHD1 variant. Cells were lysed
24 hr after transfection, and protein samples were
separated using SDS-PAGE gels containing Phos-
tag (+Phos-tag). SAMHD1 variants were detected
by western blotting using anti-FLAG antibodies. The
indicated sample was treated with lPP for detecting
the migration of the unphosphorylated SAMHD1. In
parallel, we performed a similar analysis using the
empty vector pLPCX. Protein samples were also
separated in SDS-PAGE gels without Phos-tag
(Phos-tag). As a loading control, cell lysates were
western blotted using GAPDH antibodies.
(B) The different SAMHD1 variants expressed in 293T
cells were also analyzed by western blotting using
anti-phospho-T592-SAMHD1 antibodies, which only
recognize a phosphorylated SAMHD1 protein at
residues T592.
(C) Human monocytic U937 cells were stably trans-
duced with wild-type SAMHD1 and the indicated
SAMHD1 variant. PMA-treated stable cells were
analyzed for SAMHD1 expression by western blotting
using anti-FLAG antibodies. Similarly, western blot
analysis of GAPDH was used as loading control.
(D and E) PMA-treated human monocytic U937 cells
stably expressing the indicated SAMHD1 variants
were challenged with increasing amounts of HIV-1-
GFP. Infection is shown as the percentage of GFP-
positive cells 48 hr postinfection measured by flow
cytometry. As a control, U937 cells stably transduced
with the empty vector pLPCX were challenged with
increasing amounts of HIV-1-GFP. See also Fig-
ure S2. Experiments were performed in triplicate, and
a representative result is shown. WT, Wild-type.
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HIV-1 infection.
Because our results indicated that the unphosphorylated form
of SAMHD1 blocks HIV-1 infection in noncycling cells, we tested
the ability of SAMHD1-T592V, which could not be phosphory-
lated, to restrict HIV-1 in cycling cells. As shown in Figures
S2C and S2D, expression of SAMHD1-T592V in HeLa cells did
not block HIV-1 infection. However, when SAMHD1-T592V
was tested in cycling U937 cells, it showed a mild effect on
HIV-1 infection (Figure S2E).
Finally, we tested the ability of Vpx from the ROD strain of
HIV-2 (VpxROD) to degrade the different SAMHD1 phosphoryla-
tion variants. As shown in Figure S2F, VpxROD degraded the
different SAMHD1 phosphorylation variants equally, suggesting
that the ability of VpxROD to degrade SAMHD1 is independent of
the phosphorylation state of SAMHD1.
Oligomerization, RNA Binding, and Localization of
SAMHD1 Phosphorylation Variants
Allosteric regulation of the enzymatic activity of SAMHD1 occurs
in the dimerization interface of the HD domain (Goldstone et al.,
2011). In agreement with this, we found that the SAMHD1 variant
HD206AA is partially affected in its ability to oligomerize, which
suggests that the defect in the ability of HD206AA to restrict
HIV-1 might also be due to an oligomerization deficiency (White
et al., 2013). To evaluate the possibility that the phosphorylationCell Hvariants of SAMHD1 lose restriction due to an oligomerization
defect, we tested the ability of the different SAMHD1-FLAG
variants to oligomerize with the SAMHD1-hemagglutinin (HA)
corresponding variant (Figure S2G). Interestingly, we found
that SAMHD1 variants that lost the ability to block retroviral
infection did not lose oligomerization ability, suggesting that
the inability of SAMHD1 variants to restrict retroviral infection is
not due to a defect in oligomerization.
We and others have previously demonstrated the ability of
SAMHD1 to bind RNA (Goncalves et al., 2012; White et al.,
2013); therefore, we tested the ability of the different SAMHD1
phosphorylation variants produced in human 293T cells to bind
RNA (Figure S2H), as described previously (White et al., 2013).
As shown inFigureS2H, all the studiedSAMHD1phosphorylation
variants showed the ability to bind the double-stranded RNA
(dsRNA) analogphosphorothioate-containing interferon-stimula-
tory DNA (ISD-PS) as strongly as the wild-type SAMHD1 protein.
Finally, we tested the cellular localization of the different
SAMHD1 phosphorylation variants in human HeLa cells (Fig-
ure S2I), as described previously (Brandariz-Nun˜ez et al., 2012;
White et al., 2013). These results showed that all the studied
SAMHD1 phosphorylation variants localized to the nuclear
compartment, similarly to the wild-type SAMHD1 protein (Fig-
ure S2I). Overall, these results demonstrated that the SAMHD1
phosphorylation variants used in these studies do not exhibit a
major defect in the different properties of SAMHD1.ost & Microbe 13, 441–451, April 17, 2013 ª2013 Elsevier Inc. 445
Figure 4. Role of the N-Terminal Residues 1–112 in the Ability of
Phosphorylation to Regulate Retroviral Restriction
(A) Human 293T cells were transfected with the indicated SAMHD1 variant.
Cells were lysed 24 hr after transfection, and protein samples were separated
using SDS-PAGE gels containing Phos-tag (+Phos-tag). SAMHD1 variants
were detected by western blotting using anti-FLAG antibodies. Protein sam-
ples were also separated in SDS-PAGE gels without Phos-tag (Phos-tag). As
a loading control, cell lysates were western blotted using GAPDH antibodies.
(B) Human monocytic U937 cells were stably transduced with wild-type, and
the indicated SAMHD1 variants were analyzed for SAMHD1 expression by
western blotting using anti-FLAG antibodies. Western blot analysis of GAPDH
was used as a loading control.
(C) Human monocytic U937 cells stably expressing the different SAMHD1
variants were challenged with increasing amounts of HIV-1-GFP. Infection
is shown as the percentage of GFP-positive cells 48 hr postinfection as
measured by flow cytometry. As a control, U937 cells stably transduced with
the empty vector pLPCX were challenged with increasing amounts of HIV-1-
GFP. See also Figure S3. Experiments were performed in triplicate, and a
representative result is shown.
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Regulation of Retroviral Restriction by Phosphorylation
of T592
Because our observations suggested that the phosphorylation
state of T592 regulates the ability of SAMHD1 to block retroviral
restriction, we tested the role of the N-terminal residues (1–112)
of SAMHD1 (Figure 1B) in the ability of T592 phosphorylation to
regulate restriction. Our previous observations suggested that a
construct containing SAMHD1 residues 112–626 is sufficient for
potent restriction of HIV-1 (White et al., 2013). To test the role
of residues 1–112 in SAMHD1 regulation by phosphorylation,
we created a construct containing the residues 112–626 of
SAMHD1 wherein T592 was replaced by the phosphomimetic
residue D (112-626-T592D). The phosphorylation levels of 112–
626 and 112-626-T592D were measured in human 293T cells
via western blotting using SDS-PAGE gels containing Phos-tag
(Figure 4A). In agreement with our findings in the full-length
SAMHD1, the protein composed of residues 112–626 was
phosphorylated (Figure 4A). Interestingly, 112-626-T592D re-
vealed an unphosphorylated protein similar to the full-length
SAMHD1-T592D in noncycling cells (Figure 4A). To test the
ability of 112-626-T592D to block HIV-1 infection, we stably ex-
pressed it in U937 cells (Figure 4B) and challenged cells with
increasing amounts of HIV-1-GFP (Figure 4C). Interestingly,
112-626-T592D completely lost its ability to block HIV-1 infec-
tion when compared to 112–626 or full-length SAMHD1 (Fig-
ure 4C). Our results indicate that the SAMHD1 N-terminal resi-
dues 1–112 are dispensable for the ability of the T592
phosphorylation to regulate retroviral restriction.
Level of Cellular dNTPs in U937 Cells Stably Expressing
the Different SAMHD1 Phosphorylation Variants
Previous observations have suggested that SAMHD1 blocks
HIV-1 replication by decreasing the intracellular pool of dNTPs
(Goldstone et al., 2011; Kim et al., 2012; Lahouassa et al.,
2012; Powell et al., 2011; White et al., 2013). A decrease in
cellular dNTPs will prevent the occurrence of retroviral reverse
transcription, a process that requires dNTPs. Given that
SAMHD1 phosphorylation variants did not show an obvious
defect of the known properties of SAMHD1, we decided to test
whether the loss of restriction by SAMHD1 phosphorylation
variants correlated with a gain in cellular dNTP levels. For this
purpose, we measured the intracellular levels of dNTPs in differ-
entiated U937 cells stably expressing the different SAMHD1
phosphorylarion variants (Figure 5A), as described previously
(White et al., 2013). Remarkably, U937 cells stably expressing
SAMHD1 variants wherein T592 was replaced by a phosphomi-
metic residue (D or E) showed dNTP levels comparable to those
of U937 cells stably expressing wild-type SAMHD1. In agree-
ment with this, the cellular dNTP levels of U937 cells stably
expressing the SAMHD1 construct 112-626-T592D, which loses
the ability to block HIV-1 infection, were similar to the levels
found in U937 cells stably expressing wild-type SAMHD1 (Fig-
ure S3 and Table 1). These results indicate that the inability
of SAMHD1-T592D, SAMHD1-T592E, and 112-626-T592D to
block HIV-1 infection is not due to a defect in the dNTPase activ-
ity of the protein. These findings indirectly suggest that the
dNTPase activity of SAMHD1-T592D, SAMHD1-T592E, and
112-626-T592D is intact.446 Cell Host & Microbe 13, 441–451, April 17, 2013 ª2013 ElsevierEnzymatic Activity of the Different SAMHD1
Phosphorylation Variants
To directly analyze the enzymatic activity of SAMHD1 phosphor-
ylation variants, we tested the ability of immunoprecipitated
SAMHD1 variants (Figure 5B) to hydrolyze a-32P-labeled thymi-
dine triphosphate (a-[32P]TTP) to deoxythymidine (dT) and
a-[32P]PP, in the presence of the allosteric activator dGTP (Fig-
ure 5C). For this purpose, we incubated the indicated SAMHD1
variant in the presence of radio-labeled a-[32P]TTP. Reaction
products were separated using thin-layer chromatography in
order to determine the amount of hydrolyzed a-[32P]PP (Fig-
ure 5C), as previously shown (White et al., 2013). In agreement,
immunoprecipitated SAMHD1-T592D and SAMHD1-T592E ex-
hibited similar enzymatic activity when compared to wild-type
SAMHD1 (Figure 5C). As a control, we measured the enzymatic
activity of the different SAMHD1 variants in the presence of anInc.
Figure 5. Analysis of Enzymatic Activity of the Different SAMHD1 Variants
(A) Quantification of dATP, dTTP, and dGTP levels from PMA-treated U937 cells expressing the indicated SAMHD1 variants was performed with a primer-
extension assay, as described in Experimental Procedures. Similar results were obtained in three separate experiments, and a representative experiment is
shown.
(B) Immunoprecipitated SAMHD1 variants from human 293T cells were normalized by western blotting using anti-FLAG antibodies. WT, wild-type; WB, western
blot; IP, immunoprecipitation.
(C) Thin-layer chromatography analysis of the dTTP-triphosphohydrolase activity of the different immunoprecipitated SAMHD1 variants. For this purpose, we
incubated radio-labeled a-[32P]dTTP in the presence of the indicated SAMHD1 variants. Products from the a-[32P]dTTP hydrolysis were separated by thin-layer
chromatography using polyethyleneimine cellulose. Hydrolysis of a-[32P]dTTP yields dT and a-[32P]PP, which are visualized by using a phosphoimager. As a
control, we also measured the dTTP-triphosphohydrolase activity in the presence of the dsRNA analog ISD-PS. The results of three independent enzymatic
reactions per treatment are shown.
(D) Recombinant SAMHD1 and SAMHD1-T592D proteins were purified from baculovirus-infected Sf9 insect cells. Proteins were separated by SDS-PAGE gels
and stained with Coomassie blue.
(E) Similarly, the dTTPase activity of baculovirus recombinant SAMHD1 and SAMHD1-T592D proteins was determined by measuring the hydrolysis of radio-
labeled a-[32P]dTTP of the indicated recombinant SAMHD1 protein. Reactions were stopped at the indicated times and separated by thin-layer chromatography
using polyethyleneimine cellulose, as described in Experimental Procedures. See also Figure S4. A representative result of three independent experiments is
shown.
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SAMHD1 (White et al., 2013). These experiments showed that
the enzymatic activity of SAMHD1 phosphorylation variants is
not affected. We also confirmed these results by measuring
nucleotide hydrolysis via high-pressure liquid chromatographyCell H(HPLC) (Figure S4A), as described in Experimental Procedures.
Overall, these findings suggest that the enzymatic activity of
SAMHD1 is not sufficient for restriction of HIV-1. Similarly, we
measured the ability of SAMHD1-T592D purified from insect
cells to hydrolyze a-[32P]TTP in the presence of the allostericost & Microbe 13, 441–451, April 17, 2013 ª2013 Elsevier Inc. 447
Figure 6. Involvement of cdk1 in the Phosphorylation of SAMHD1
(A) Effect of the Cdk1 dominant-negative mutant D146N (Cdk1-D146N)
on the phosphorylation levels of SAMHD1. Cell lysates from human
293T cells transfected with plasmids expressing the SAMHD1-FLAG and
Cdk1-D146N-HA proteins were separated by SDS-PAGE containing Phos-
tag (+Phos-tag). SAMHD1-FLAG and Cdk1-D146N-HA were detected by
western blotting using anti-FLAG and anti-HA antibodies, respectively.
As a control, the levels of SAMHD1 phosphorylation were determined in
the presence of the empty vector pCMV. Protein samples were also
separated in SDS-PAGE gels without Phos-tag (Phos-tag). Loading was
normalized by western blotting using GAPDH antibodies. Similar results were
obtained in three independent experiments, and a representative experiment
is shown.
(B) In vitro phosphorylation of recombinant GST-SAMHD1 purified from
bacteria by cdk1 complex, which was purified from baculovirus-infected
cells using g-[32P]ATP as a phosphate donor. As a positive control, we
incubated the cdk1 kinase complex with the human histone H1, which
is a known substrate for this kinase complex. As a negative control, we
incubated a similar amount of purified GST protein with the kinase com-
plex cdk1.
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shown (White et al., 2013). In agreement, purified SAMHD1-
T592D showed similar a-[32P]TTP hydrolyse activity when
compared to the wild-type purified protein (Figures 5D, 5E, and
S4C). In the same way, we confirmed these results by measuring
nucleotide hydrolysis via HPLC (Figure S4B).
Involvement of Cyclin-Dependent Kinase 1 in the
Phosphorylation of SAMHD1
Covalent capture of kinase-specific phosphopeptides from
total HeLa extracts revealed that a peptide derived from
SAMHD1 containing T592 is the substrate for the human cdk1
complex (Blethrow et al., 2008). These experiments suggested
that human cdk1 might be the cellular kinase of SAMHD1. In
agreement, analysis of the SAMHD1 protein sequence with
the software Scansite (http://scansite.mit.edu) revealed that
residues 592TPQK595 constitute a consensus sequence motif
for recognition and phosphorylation by cdk1 (Errico et al.,
2010). To test the role of cdk1 in phosphorylation of SAMHD1,
we assayed the level of SAMHD1 phosphorylation in the
presence of the human dominant-negative cdk1 mutant cdk1-
D146N, which is a cdk1-defective variant on its active site
(van den Heuvel and Harlow, 1993). As shown in Figure 6A,
the presence of Cdk1-D146N decreased the amount of
phosphorylated SAMHD1, suggesting that human cdk1 is phos-
phorylating SAMHD1 in vivo. To directly test the ability of human
cdk1 to phosphorylate SAMHD1, we incubated bacterially ex-
pressed recombinant glutathione S-transferase (GST)-SAMHD1
with an active cdk1 complex in an in vitro kinase assay (Fig-
ure 6B). These experiments showed that cdk1 phosphorylates
GST-SAMHD1, but not the GST control protein. We performed
a similar in vitro kinase assay using the human histone H1,
which is a specififc substrate for the cdk1 complex, as a positive
control. These results, together with the evidence that SAMHD1
variants on T592 are not phosphorylated in vivo (Figures 3A
and 3B), suggest that SAMHD1 is a substrate for the kinase
complex cdk1. The results are also in agreement with the ob-
servation that mutating P593A in the cdk1 recognition motif
592TPQK595 abrogates SAMHD1 phosphorylation (Figure 3).
The SAMHD1-P593A protein behaved similarly to SAMHD1-
T592A/V, suggesting that this mutant lost its ability to be regu-
lated by phosphorylation (Figures 3 and 5).
DISCUSSION
Cycling and noncycling cells have the potentiality to express the
restriction factor SAMHD1; however, SAMHD1 is only antivirally
active in noncycling cells, suggesting that differences exist
between cycling and noncycling cells that might be regulating
the ability of SAMHD1 to block retroviral infection. The first
possible explanation is that SAMHD1 is posttranslationally modi-
fied when comparing cycling with noncycling cells. Second,
noncycling cells might be expressing a cofactor required for
restriction, and a third possibility would be that SAMHD1 post-
translational modifications and a cofactor are required for retro-
viral restriction. The present work revealed that the ability of
SAMHD1 to restrict retroviral infection is regulated by phosphor-
ylation of T592. Interestingly, we found that all tested cycling
cells expressed a SAMHD1 protein phosphorylated at residue448 Cell Host & Microbe 13, 441–451, April 17, 2013 ª2013 Elsevier Inc.
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phosphorylated SAMHD1 protein at position T592.
The replacement of T592 with phosphomimetic amino acids
completely abrogated the ability of SAMHD1 to block retroviral
infection. SAMHD1 phosphorylation variants T592D and T592E
completely lost their capacity to block retroviral infection without
losing RNA binding, dNTPase activity, oligomerization, and
localization. The fact that these variants did not lose most of
the known SAMHD1 properties suggests that these variants
are properly folded. One possibility is that phosphorylation of
SAMHD1 at residue T592 induces a conformational change
that eliminates the ability of SAMHD1 to block retroviral infection
without affecting all the known properties of SAMHD1. A second
possibility is that phosphorylation of residue T592 regulates the
ability of SAMHD1 to interact with an unknown cofactor required
for retroviral restriction.
The ability of phosphorylation to regulate the restriction
capacity of SAMHD1 only requires the HD domain and the
C-terminal residues 583–626 (Figure 1B). Previous studies
showed that a SAMHD1 construct containing only the HD
domain and the C-terminal residues 583–626 (112–626) is suffi-
cient for potent restriction of retroviruses (White et al., 2013); this
work suggested that the SAM domain is dispensable for restric-
tion. Our investigations revealed that the SAMHD1 construct
112–626 wherein T592 has been replaced by a phosphomimetic
residue loses its restriction capacity, suggesting that regulation
of restriction by phosphorylation does not require the N-terminal
residues 1–112. In agreement with this, 112-626-T592D lost
the ability to block retroviral infection without losing dNTPase
activity.
Several lines of evidence have correlated the ability of
SAMHD1 to decrease the levels of dNTPs with the ability of
SAMHD1 to block infection by different retroviruses, suggesting
that decreasing the cellular levels of dNTPs is what limits viral
replication (Goldstone et al., 2011; Kim et al., 2012; Lahouassa
et al., 2012; Powell et al., 2011; White et al., 2013). The present
work found SAMHD1 variants that lost their ability to block retro-
viral infection but preserved the ability to decrease the cellular
dNTP levels. In addition, these variants were also proven to
be enzymatically active when tested as a purified protein from
insect or mammalian cells. These results indicated that the
decrease of cellular dNTP levels by SAMHD1 is not sufficient
to achieve retroviral restriction. One possible explanation is
that both the enzymatic activity of SAMHD1 and an unknown
function is required for restriction. A second possibility is that
the enzymatic activity of SAMHD1 is not necessary for the ability
of SAMHD1 to block retroviral infection. Although the variant
HD206AA, which targets the active site of SAMHD1, loses
retroviral restriction (Hrecka et al., 2011; Laguette et al., 2011),
its oligomerization capacity is also defective, making it dif-
ficult to pinpoint which defect causes loss of restriction
(White et al., 2013). In addition, these results implied that
decreasing the levels of cellular dNTPs to the levels achieved
by wild-type SAMHD1 is not sufficient to block infection by
different retroviruses.
Recent observations have suggested that SAMHD1 exhibits 30
to 50 exonuclease activity against single-stranded DNA and RNA
in vitro (Beloglazova et al., 2013). An alternative possibility is that
phosphorylated SAMHD1 at position T592 exhibits low exonu-Cell Hclease activity without losing the ability to decrease the cellular
levels of dNTPs. By contrast, a dephosphorylated SAMHD1
would exhibit high exonuclease activity. This would suggest
that SAMHD1 is stopping viral replication by degrading the
genetic material of the virus, which is in agreement with the
ability of SAMHD1 to restrict diverse RNA viruses such as lenti-
viruses and g-retroviruses (White et al., 2013). Future experi-
ments will attempt to understand whether the enzymatic activity
of SAMHD1 is required for restriction.
Previous observations demonstrated that residue T592 is the
substrate of the human cdk1 complex in HeLa cells (Blethrow
et al., 2008). In agreement with this, residues 592TPQK595 are a
consensus sequence motif for recognition and phosphorylation
by cdk1 (Errico et al., 2010), and replacement of T592 in the
592TPQK595 motif by an unphosphorytable residue diminishes
the ability of SAMHD1 to become phosphorylated in human
cycling cells. Similarly, the replacement of P593 in the same
motif by an alanine diminished SAMHD1 phosphorylation. To
confirm this evidence, we assayed the level of SAMHD1 phos-
phorylation in the presence of the human dominant-negative
cdk1 mutant (cdk1-D146N) to show that expression of the
cdk1 dominant-negative mutant decreases the level of phos-
phorylated wild-type SAMHD1.We also demonstrated the ability
of purified cdk1 complex to phosphorylate purified SAMHD1. In
agreement with these findings, several groups have reported
that differentiation of cells to a noncycling state involves the
downmodulation of cdk1 expression (Hass et al., 1992; Kim
et al., 2008; Traore et al., 2005). However, a phosphatase might
also be regulating the phosphorylation state of SAMHD1 at posi-
tion T592. Even though in most of the known cases regulation by
phosphorylation is determined by the kinase, there are examples
wherein the phosphatase plays an important role in regulating
the phosphorylation state of a particular protein (Cheng et al.,
2011). Future experiments will attempt to understand whether
the phosphorylation of SAMHD1 is regulated by cellular phos-
phatases. Taken together, this evidence suggests that SAMHD1
is the substrate of cdk1 in human cycling cells, and that the
downmodulation of cdk1 in noncycling cells results in the pres-
ence of unphosphorylated SAMHD1 protein, which is antivirally
active.
EXPERIMENTAL PROCEDURES
Generation of U937 Cells Stably Expressing SAMHD1 Variants
Retroviral vectors encoding wild-type or mutant SAMHD1 proteins were
created using the LPCX vector. Recombinant viruses were produced in 293T
cells by cotransfecting the LPCX plasmids with the pVPack-GP and pVPack-
VSV-G packaging plasmids. Transduced human monocytic U937 cells were
selected in 0.4 mg/ml puromycin.
Infection with Retroviruses Expressing GFP
Recombinant retroviruses expressing GFP, pseudotyped with the VSV-G
glycoprotein, were prepared as described (Diaz-Griffero et al., 2008). For
infections, 6 3 104 cells were seeded in 24-well plates and treated with
PMA. Subsequently, cells were incubated with the indicated retrovirus for
48 hr. The percentage of GFP-positive cells was determined by flow cytometry
(Becton Dickinson).
SAMHD1 Oligomerization Assay
Human 293T cells were cotransfected with plasmids encoding SAMHD1
variants tagged with FLAG and HA. Precleared lysates containing SAMHD1ost & Microbe 13, 441–451, April 17, 2013 ª2013 Elsevier Inc. 449
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beads were washed three times, and immune complexes were eluted using
a FLAG tripeptide. The eluted samples were analyzed by western blotting
using either anti-HA or anti-FLAG antibodies.
Nucleic-Acid Binding Assay
The nucleic-acid binding assay was performed as previously described (Gon-
calves et al., 2012; White et al., 2013). In brief, the synthetic-DNA ISD-PS,
which is an RNA analog, was used. Precleared lysates (‘‘Input’’ in Figure S2)
were incubated with immobilized nucleic acids in the presence of calf-thymus
DNA as a competitor. Unbound proteins were removed by three consecutive
washes. Bound proteins to nucleic acids (‘‘Bound’’) were eluted and analyzed
by western blotting using FLAG antibodies.
Cellular dNTPs Quantification by a Primer Extension Assay
Cells were pelleted, resuspended on ice-cold methanol, and dried using a
SpeedVac. The dried samples were resuspended in water, and analyzed for
dNTP content, as described previously (Kim et al., 2012; Lahouassa et al.,
2012).
Immunoprecipitation and Mass Spectrometry
U937 cells stably expressing SAMHD1-FLAG, THP-1 cells, or primary MDMs
were lysed and precleared using protein A-agarose. Precleared lysates were
incubated with anti-FLAG-agarose beads or protein A-agarose with the anti-
SAMHD1 antibody when appropriate. Beads containing the immunoprecipi-
tates were washed three times. Subsequently, immune complexes were
eluted and samples were separated by SDS-PAGE. Bands corresponding to
the molecular weight of SAMHD1 were excised and sent to the Taplin Mass
Spectrometry Facility (Harvard Medical School) for phosphopeptide mapping.
SDS-PAGE Gels Containing Phos-Tag
Preparation of Phos-tag gels was performed as previously described (Kinosh-
ita et al., 2006). The gel consisted of a separating and a stacking gel containing
Zn-Phos-tag. The acrylamide-pendant Phos-tag ligand and two equivalents of
Zn(NO3)2 were added to the separating gel before polymerization. After elec-
trophoresis, the gel was transferred to a nitrocellulose membrane using an
iBlot Gel Transfer system.
In Vitro cdk1 Complex Kinase Assay
Recombinant GST-SAMHD1 or GST was incubated with recombinant cdk1
complex (Sigma-Aldrich) in phosphorylation buffer suplemented with 5 mCi
of g-[32P]ATP. The phosphorylation reaction was stopped by the addition of
sample buffer. Proteins were resolved on 10% polyacrilamide SDS-PAGE.
The resultant gel was dryed on a Bio-Rad gel dryer and analyzed using a
phosphoimager.
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